DBI Protein Modulation Methods for Autophagy and Metabolic Regulation

Thu, 09 Apr 2026 12:25:57 +0000
Intellectual Property

The USPTO published patent application US20260097094A1 disclosing methods for modulating diazepam binding inhibitor (DBI) protein activity to regulate autophagy and metabolic processes. The inventors demonstrate that DBI neutralization via monoclonal antibodies or active immunization induces autophagy, enhances starvation-induced weight loss, reduces food intake upon refeeding, and reduces weight gain from hypercaloric diets. The patent covers pharmaceutical compositions and therapeutic applications for metabolic disorders.